Invivyd Reports Strong Q2 Growth Amid Key Clinical Trial Milestones
Event summary
- Invivyd reported Q2 2026 net product revenue of $14.3M, up 21% YoY from $11.8M.
- Completed enrollment in DECLARATION and LIBERTY clinical trials for VYD2311.
- Cash position stands at $160.1M as of Q2 2026, providing runway through pivotal data readouts.
- Received advanced notice of EUA termination for PEMGARDA, engaging in FDA dialogue on next steps.
The big picture
Invivyd's Q2 results highlight its ability to grow PEMGARDA revenue despite declining COVID vaccine utilization. The company is now pivoting toward potential commercialization of VYD2311, a monoclonal antibody alternative for COVID-19 prophylaxis. With key clinical trials nearing completion and a strong cash position, Invivyd is positioning itself in the evolving landscape of viral disease prevention, where non-vaccine options are increasingly valued by public health leaders.
What we're watching
- Regulatory Transition
- How the FDA's EUA termination for PEMGARDA will impact Invivyd's commercial strategy and patient access.
- Clinical Trial Outcomes
- Whether top-line data from DECLARATION and LIBERTY trials will support a BLA submission for VYD2311.
- Market Positioning
- The pace at which Invivyd can advance its pipeline, including measles and RSV candidates, to diversify revenue streams.
Related topics